Immune restoration in HIV-positive, antiretroviral-naive patients after 1 year of zidovudine/lamivudine plus nelfinavir or nevirapine

Antiviral Therapy

Volumn 9, Issue 2, 2004, Pages 197-204

  Plana, Montserrat ^a   Ferrer, Elena ^b   Martínez, Catalina ^a   Podzamczer, Daniel ^b   García, Felipe ^a   Maleno, María J ^a   Barceló, Juan J ^a   García, Ana ^a   Barberá, María J ^b   Lacarcel, Montserrat ^b   Miró, José M ^a   Gallart, Teresa ^a   Gatell, José M ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CD28 ANTIGEN; CD38 ANTIGEN; CD4 ANTIGEN; CD45 ANTIGEN; CD8 ANTIGEN; GAG PROTEIN; GLYCOPROTEIN GP 160; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; ZIDOVUDINE;

ADULT; AGED; ARTICLE; CELL PROLIFERATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DRUG MECHANISM; EVALUATION; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN STUDY; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; VALIDATION PROCESS; VIRUS LOAD;

ADULT; AGED; ANTI-HIV AGENTS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HIV SEROPOSITIVITY; HUMANS; LAMIVUDINE; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; NELFINAVIR; NEVIRAPINE; REVERSE TRANSCRIPTASE INHIBITORS; T-LYMPHOCYTE SUBSETS; ZIDOVUDINE;

EID: 2342423035     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Haynes BF, Pantaleo G & Fauci AS. Toward an understanding of the correlates of protective immunity to HIV infection. Science 1996; 271:324-328.
2. Wong MT, Dolan MJ, Kozlow E, Doe R, Melcher GP, Burke DS, Boswell RN & Vahey M. Patterns of virus burden and T cell phenotype are established early and are correlated with the rate of disease progression in human immunodeficiency virus type-1 infected persons. Journal of Infectious Diseases 1996; 173:877-888.
3. Yeni PG, Hammer SM, Carpenter CC, Cooper DA, Fischl MA, Gatell JM, Gazzard BG, Hirsch MS, Jacobsen DM, Katzenstein DA, Montaner JS, Richman DD, Saag MS, Schechter M, Schooley RT, Thompson MA, Vella S & Volberding PA. Antiretroviral treatment for adult HIV infection in 2002. Updated recommendations of the International AIDS Society-USA panel. Journal of the American Medical Association 2002; 288:222-235.
4. Garcia F, Alonso MM, Romeu J, Knobel H, Arrizabalaga J, Ferrer E, Dalmau D, Ruiz I, Vidal F, Frances A, Segura F, Gomez-Sirvent JL, Cruceta A, Clotet B, Pumarola T, Gallart T, O'Brien WA, Miro JM & Gatell JM. Comparison of immunological restoration and virological response in plasma, tonsillar tissue and cerebrospinal fluid in HIV-1 infected patients treated with double versus triple antiretroviral therapy in very early stages. The Spanish Earth-2 Study. Journal of the Acquired Immune Deficiency Syndromes 2000; 25:26-35.
5. Garcia F, Romeu J, Grau I, Sambeat MA, Dalmau D, Knobel H, Gomez-Sirvent JL, Arrizabalaga J, Cruceta A, Clotet BG, Podzamczer D, Pumarola T, Gallart T, O'Brien WA, Miro JM & Gatell JM. A randomized study comparing triple versus double antiretroviral therapy or no treatment in HIV-1-infected patients in very early stage disease: the Spanish Earth-1 study. AIDS 1999; 13:2377-2388.
6. Garcia F, Knobel H, Sambeat MA, Arrizabalaga J, Aranda M, Romeu J, Dalmau D, Segura F, Gomez-Sirvent JL, Ferrer E, Cruceta A, Gallart T, Pumarola T, Miro JM & Gatell JM; Spanish SCAN Study Group. An open randomized study comparing d4T plus ddI and nevirapine (QD) vs d4T plus ddI and nevirapine (BID) in antiretroviral naive chronic HIV-1 infected patients in very early stages (Spanish SCAN Study). AIDS 2000; 14:2485-2494.
7. Autran B, Carcelain G, Tubiana R, Calvez V, Mallet A, Debre P & Katlama C. Effects of antiretroviral therapy on immune reconstitution. 6th Conference on Retroviruses & Opportunistic Infections. Chicago, Ill., USA, 1999.
8. Plana M, Garcia F, Gallart T, Tortajada C, Soriano A, Palou E, Maleno MJ, Barcelo JJ, Vidal C, Cruceta A, Miro JM & Gatell JM. Immunologic benefits of antiretroviral therapy In very early stages of asymptomatic chronic HIV-1 infection. AIDS 2000; 14:1921-1933.
9. Autran B, Carcelain G, Li TS, Blanc C, Mathez D, Tubiana R, Katlama C, Debré P & Leibowitz J. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science 1997; 277:112-116.
10. Pakker NG, Notermans DW, de Boer RJ, Roos MTL, de Wolf F, Hill A, Leonard JM, Danner SA, Miedema F & Schellekens PTA. Biphasics kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: a composite of redistribution and proliferation. Nature Medicine 1998; 4(2):208-214.
11. Lederman MM, Connick E, Landay A, Kuritzkes DR, Spritzler J, St Clair M, Kotzin BL, Fox L, Heath Chiozzi M, Leonard JM, Rousseau F, Wade M, Roe J, Martinez A & Kessler H. Immunologic responses associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine, and rironavir: results of AIDS clinical trials group protocol 315. Journal of Infectious Diseases 1998; 178:70-79.
12. Li TS, Tubiana R, Katlama C, Calvez V, Ait Mohand H & Autran B. Long-lasting recovery in CD4 T-cell function and viral-load reduction after hightly active antiretroviral therapy in advanced HIV-1 disease. Lancet 1998; 351:1682-1686.
13. Staszewski S, Morales-Ramirez J, Tashima KT, Rachlis A, Skiest D, Stanford J, Stryker R, Johnson P, Labriola DF, Farina D, Manion DJ & Ruiz NM. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. New England Journal of Medicine 1999; 341:1865-1873.
14. Montaner JS, Reiss P, Cooper D, Vella S, Harris M, Conway B, Wainberg MA, Smith D, Robinson P, Hall D, Myers M & Lange JM. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study. Journal of the American Medical Association 1998; 279:930-937.
15. Plana M, Martínez C, García F, Maleno MJ, Barceló JJ, García A, Lejeune M, Vidal C, Cruceta A, Miró JM, Pumarola T, Gallart T & Gatell JM. Immunological reconstitution after one year of highly active antiretroviral therapy with or without protease inhibitors. Journal of Acquired Immune Deficiency Syndromes 2002; 29:429-434.
16. Pakker NG, Kroon EDMB, Roos MTL, Otto SA, Hall D, Wit FWNM, Hamann D, van der Ende ME, Claessen FAP, Kauffmann RH, Koopmans PP, Kroon FP, ten Napel CHH, Sprenger HG, Weigel HM, Montaner JSG, Lange JMA, Reiss P, Schellekens PTA & Miedema F for the INCAS study group. Immune restoration does not invariably occur following long-term HIV-1 suppression during antiretroviral therapy. AIDS 1999; 13(2):203-212.
17. Podzamczer D, Ferrer E, Consiglio E, Gatell JM, Perez P, Perez JL, Luna E, Gonzalez A, Pedrol E, Lozano L, Ocaña I, Llibre JM, Casiró A, Aranda M, Barrufet P, Martínez-Lacasa J, Miró JM, Badía X, Casado A, Lupo S, Cahn P, Maños M, Estela J & the Combine Study team. A randomized clinical trial comparing nelfinavir or nevirapine associated to ZDV/3TC in HIV-infected naive patients (The Combine study). Antiviral Therapy 2002; 7:81-90.
18. Schockmel G, Yerly S & Perrin L. Detection of low HIV-1 RNA levels in plasma. Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology 1997; 14:179-183.
19. Hammer SM, Squires KE, Hughes MD, Grimes JM, Demeter LM, Currier JS, Eron JJ Jr, Feinberg JE, Balfour HH Jr, Deyton LR, Chodakewitz JA & Fischl MA. Controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200/ml or less. New England Journal of Medicine 1997; 337:725-733.
20. Angel JB, Parato KB, Kumar A, Kravcik S, Badley AD, Fex C, Ashby D, Sun E & Cameron DW. Progressive human immunodeficiency virus-specific immune recovery with prolonged viral suppression. Journal of Infectious Diseases 2001; 183:546-554.
21. Barreiro P, Soriano V, Casas E & González-Lahoz J. Different degree of immune recovery using antiretroviral regimens with protease inhibitors or non-nucleosides. AIDS 2002; 16:245-249.
22. Plana M, Garcia F, Gallart MT, Miro JM & Gatell JM. Lack of T-cell proliferative response to HIV-1 antigens after one year of HAART in very early HIV-1 disease. Lancet 1998; 352:1194-1195.
23. Finzi D, Hermankova M, Pierson T, Carruth LM, Buck C, Chaisson RE, Quinn TC, Chadwick K, Margolick J, Brookmeyer R, Gallant J, Markowitz M, Ho DD, Richman DD & Siliciano RF. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 1997; 278:1295-1300.